QC
VTGN icon

Quadrature Capital’s VistaGen Therapeutics VTGN Stock Holding History

Quadrature Capital’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,752
Closed -$55.8K – 1692
2025
Q3 		$55.8K Buy
+15,752
New +$47.1K ﹤0.01% 947

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LM
Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Quadrature Capital's VTGN Position: Q4 2025 in Review

Quadrature Capital sold out of VistaGen Therapeutics (VTGN) in Q4 2025, closing a stake of 15,752 shares — an estimated $55.8K sold.

Quadrature Capital first reported a position in VTGN in Q3 2025 and held it in 1 quarter. The position peaked at $55.8K in Q3 2025. 55 funds tracked by Wall St. Rank hold VTGN as of Q4 2025.

  • Quadrature Capital reported no remaining VistaGen Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Quadrature Capital sold 15,752 VistaGen Therapeutics shares in Q4 2025, an estimated $55.8K.
  • Quadrature Capital first reported a position in VistaGen Therapeutics in Q3 2025 and held it in 1 quarter.
  • Quadrature Capital's VistaGen Therapeutics position peaked at $55.8K in Q3 2025.
  • 55 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2025.

Based on Quadrature Capital's 13F filing for Q4 2025, filed 17 Feb 2026.